专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2005145959A Phospholipid membrane formulation 有权
标题翻译：磷脂膜配方
公开(公告)号：JP2005145959A
公开(公告)日：2005-06-09
申请号：JP2004305217
申请日：2004-10-20
申请人： National Institute Of Infectious Diseases , Nof Corp , 国立感染症研究所長 , 日本油脂株式会社
发明人： UCHIDA TETSUYA , MORI MASATO
IPC分类号： A61K9/127 , A61K39/00 , A61K39/35 , A61K47/24 , A61K47/28
摘要： PROBLEM TO BE SOLVED: To provide a phospholipid membrane formulation having an immunoresponse-regulating function to increase practically sufficient production of IgG antibodies by suppressing production of IgE antibodies and used as a vaccine for treating allergy or a vaccine difficult to cause allergy reaction. SOLUTION: In the phospholipid membrane formulation, antigens or allergens are bonded to the surface of the phospholipid membrane containing phospholipids having 10-12C acyl groups or hydrocarbon groups and a stabilizer for the phospholipids. COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：要解决的问题：提供具有免疫应答调节功能的磷脂膜制剂，通过抑制IgE抗体的产生来增加实际上足够的IgG抗体产生并用作治疗过敏的疫苗或难以引起过敏反应的疫苗。解决方案：在磷脂膜制剂中，将抗原或过敏原与含有10-12个碳酰基或烃基的磷脂和磷脂稳定剂的磷脂膜的表面结合。版权所有（C）2005，JPO＆NCIPI

2. 发明专利

JP2004043332A Oral liposome preparation 审中-公开
标题翻译：口服制剂
公开(公告)号：JP2004043332A
公开(公告)日：2004-02-12
申请号：JP2002200553
申请日：2002-07-09
申请人： National Institute Of Infectious Diseases , Nof Corp , 国立感染症研究所長 , 日本油脂株式会社
发明人： UCHIDA TETSUYA , MORI MASATO
IPC分类号： A61K9/127 , A61K39/00 , A61K39/35 , A61P37/08
摘要： PROBLEM TO BE SOLVED: To provide an oral liposome preparation which has an immune response-adjusting function comprising inhibiting the production of IgE antibody and increasing the production of IgG and can be used for allergy treatments or for vaccines hardly causing allergic reactions.
SOLUTION: This oral liposome preparation used for vaccines or allergy treatments is characterized by binding an antigen or an allergen to the surface of the liposome. The oral liposome used for the vaccines or allergy treatments has reinforcing effects on the production of IgE antibody and increasing the production of IgG, when orally taken. The method for adjusting an immune response comprises orally administering the liposome preparation to an animal except man.
COPYRIGHT: (C)2004,JPO
摘要翻译：要解决的问题：提供具有免疫应答调节功能的口服脂质体制剂，其包括抑制IgE抗体的产生和增加IgG的产生，并且可以用于过敏治疗或几乎不引起过敏反应的疫苗。解决方案：用于疫苗或过敏治疗的口服脂质体制剂的特征在于将抗原或变应原结合到脂质体的表面。用于疫苗或过敏治疗的口服脂质体在口服时对IgE抗体的产生具有增强作用，并增加IgG的产生。调节免疫应答的方法包括将脂质体制剂口服给除人以外的动物。版权所有（C）2004，JPO

3. 发明专利

JP2013166699A Composite body containing inactivated virus particle and use thereof 审中-公开
标题翻译：包含灭活病毒颗粒的复合体及其使用
公开(公告)号：JP2013166699A
公开(公告)日：2013-08-29
申请号：JP2010123189
申请日：2010-05-28
申请人： National Institute Of Infectious Diseases , 国立感染症研究所長 , Chemo-Sero-Therapeutic Research Inst , 一般財団法人化学及血清療法研究所 , Nof Corp , 日油株式会社
发明人： UCHIDA TETSUYA , TANEICHI MAIKO , NOZAKI CHIKAHIDE , KAMINAKA KAZUYOSHI , MIKUMA AI , YOKOYAMA SHOICHI
IPC分类号： A61K39/385 , A61K9/127 , A61K39/12 , A61K39/145 , A61K47/24 , A61K47/28 , A61K47/48 , A61P31/14 , A61P31/16 , A61P37/04
CPC分类号： A61K9/1271 , A61K39/385 , A61K47/6911 , A61K2039/5258 , A61K2039/55555
摘要： PROBLEM TO BE SOLVED: To provide a new technique for enhancing the CTL activation effect of an antigen-bound liposome.SOLUTION: A composite body which contains an inactivated virus particle, an antigen and a liposome is disclosed. In the composite body, the liposome contains a phospholipid, which has an acyl group having one unsaturated bond and 14-24 carbon atoms or a hydrocarbon group having one unsaturated bond and 14-24 carbon atoms, and a stabilizer for the liposome, and the virus particle and the antigen are bound to the surface of the liposome.
摘要翻译：要解决的问题：提供用于增强抗原结合的脂质体的CTL活化作用的新技术。解决方案：公开了含有灭活病毒颗粒，抗原和脂质体的复合体。在复合体中，脂质体含有具有一个不饱和键和14-24个碳原子的酰基或具有一个不饱和键和14-24个碳原子的烃基的磷脂和用于脂质体的稳定剂，病毒颗粒和抗原结合到脂质体的表面。

4. 发明专利

JP2014005205A Ebola virus liposome vaccine 审中-公开
标题翻译： EBOLA病毒脂蛋白疫苗
公开(公告)号：JP2014005205A
公开(公告)日：2014-01-16
申请号：JP2010231918
申请日：2010-10-14
申请人： Saitama Medical Univ , 学校法人埼玉医科大学 , National Institute Of Infectious Diseases , 国立感染症研究所長 , Nof Corp , 日油株式会社
发明人： MATSUI MASANORI , UCHIDA TETSUYA , TANEICHI MAIKO , MIKUMA AI , YOKOYAMA SHOICHI
IPC分类号： C07K7/06 , A61K9/127 , A61K38/00 , A61K39/12 , A61K47/24 , A61K47/28 , A61P31/14 , A61P37/04 , C12N5/0783 , C12N7/04
CPC分类号： A61K39/12 , A61K47/62 , A61K47/646 , A61K47/6911 , A61K2039/55555 , A61K2039/6018 , C12N2760/14134
摘要： PROBLEM TO BE SOLVED: To provide a peptide and a vaccine which can effectively induce a cytotoxic T lymphocyte to an Ebola virus antigen and can be expected to have a therapeutic effect or a preventive effect on Ebola virus infection and diseases caused by the infection.SOLUTION: The vaccine contains: a peptide which can induce a cytotoxic T lymphocyte restricted to HLA-A*0201, having an amino acid sequence represented by a specific sequence and an amino acid length of 9 to 11; or a liposome to which the peptide is bonded, containing a phospholipid having an acryl group with one unsaturated bond and a carbon number of 14 to 24 or a hydrocarbon group with one unsaturated bond and a carbon number of 14 to 24 and a stabilizer for the liposome, wherein the peptide is bonded to the surface of the liposome.
摘要翻译：要解决的问题：提供能够有效地诱导埃博拉病毒抗原的细胞毒性T淋巴细胞的肽和疫苗，并且可以预期对埃博拉病毒感染和由感染引起的疾病具有治疗作用或预防作用。：该疫苗含有：能诱导限于HLA-A * 0201的细胞毒性T淋巴细胞的肽，具有由特定序列表示的氨基酸序列，氨基酸长度为9〜11; 或肽结合的脂质体，其含有具有一个不饱和键和碳数为14〜24的丙烯酰基的磷脂或具有一个不饱和键和碳数为14〜24的烃基，以及用于脂质体，其中肽结合到脂质体的表面。

5. 发明专利

JP2011126853A Avian influenza vaccine 审中-公开
标题翻译： AVIAN INFLUENZA VACCINE
公开(公告)号：JP2011126853A
公开(公告)日：2011-06-30
申请号：JP2009289848
申请日：2009-12-21
申请人： Hokkaido Univ , National Institute Of Infectious Diseases , Nof Corp , Saitama Medical Univ , 国立大学法人北海道大学 , 国立感染症研究所長 , 学校法人埼玉医科大学 , 日油株式会社
发明人： UCHIDA TETSUYA , TANEICHI MAIKO , KAJINO KIICHI , MATSUI MASANORI , ODA HIROSHI
IPC分类号： A61K39/145 , A61K9/127 , A61K38/00 , A61K39/39 , A61K47/24 , A61K47/28 , A61P31/16 , C07K7/06
摘要： PROBLEM TO BE SOLVED: To provide a vaccine for effectively preventing infection of a highly-pathogenic avian influenza virus, that is hardly affected by viral mutation. SOLUTION: The avian influenza virus vaccine includes a liposome the surface of which is linked with a peptide. The peptide is (1) an amino acid sequence represented by sequence number 1 or 2, or (2) a peptide that contains an amino acid sequence with one or two amino acids substituted in the amino acid sequence represented by sequence number 1 or 2, and has a length of 9-11 amino acids, and can induce a cytotoxic T lymphocyte restrained by HLA. The liposome contains phospholipid having a 14-24C acyl group with one unsaturated bond or a 14-24C hydrocarbon group with one unsaturated bond, and a liposome stabilizer. COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译：要解决的问题：提供用于有效预防高致病性禽流感病毒感染的疫苗，其几乎不受病毒突变的影响。解决方案：禽流感病毒疫苗包括其表面与肽连接的脂质体。肽是（1）由序列号1或2表示的氨基酸序列，或（2）包含在序列号1或2所示的氨基酸序列中被一个或两个氨基酸取代的氨基酸序列的肽，长度为9-11个氨基酸，可诱导由HLA抑制的细胞毒性T淋巴细胞。脂质体含有具有一个不饱和键的14-24C酰基或具有一个不饱和键的14-24℃烃基和脂质体稳定剂的磷脂。版权所有（C）2011，JPO＆INPIT

6. 发明专利

JP2008037831A T-cell activating agent 审中-公开
标题翻译： T细胞活化剂
公开(公告)号：JP2008037831A
公开(公告)日：2008-02-21
申请号：JP2006217270
申请日：2006-08-09
申请人： National Institute Of Infectious Diseases , Nof Corp , 国立感染症研究所長 , 日油株式会社
发明人： UCHIDA TETSUYA , MORI MASATO , ODA HIROSHI
IPC分类号： A61K38/00 , A61K9/127 , A61K47/28 , A61P31/04 , A61P35/00 , A61P43/00
CPC分类号： A61K9/127 , A61K39/385 , A61K39/39 , A61K2039/55555
摘要： PROBLEM TO BE SOLVED: To provide a T-cell activating agent which is capable of efficiently and specifically enhancing cytotoxic T lymphocytes for killing pathogen-infected cells or tumor cells and is useful for preventing and treating infectious diseases and cancer. SOLUTION: The T-cell activator comprises an antigen-bound phospholipid membrane, wherein the phospholipid membrane comprises a phospholipid having a 14-24C acyl group having one unsaturated bond or a 14-24C hydrocarbon group having one unsaturated bond, and a phospholipid membrane stabilizer, and wherein the antigen is bound to the surface of the phospholipid membrane. COPYRIGHT: (C)2008,JPO&INPIT
摘要翻译：要解决的问题：提供能够有效和特异地增强细胞毒性T淋巴细胞以杀死病原体感染的细胞或肿瘤细胞的T细胞活化剂，并且可用于预防和治疗感染性疾病和癌症。解决方案：T细胞活化剂包括抗原结合的磷脂膜，其中磷脂膜包含具有14-24个具有一个不饱和键的酰基或具有一个不饱和键的14-24C烃基的磷脂，以及磷脂膜稳定剂，并且其中抗原结合到磷脂膜的表面。版权所有（C）2008，JPO＆INPIT

7. 发明专利

JPH09202735A LIPOSOME-TYPE ALLERGY TREATING AGENT 失效
公开(公告)号：JPH09202735A
公开(公告)日：1997-08-05
申请号：JP1119796
申请日：1996-01-25
申请人： NOF CORP , NAT INST HEALTH
发明人： NAKANO YOSHIRO , UCHIDA TETSUYA
IPC分类号： A61K9/127 , A61K39/00 , A61K39/35 , A61K39/36 , A61K39/385 , A61K47/24 , A61P37/08
摘要： PROBLEM TO BE SOLVED: To obtain the subject treating agent composed of a liposome containing an antigen immobilized exclusively in the outer water-phase of a specific liposome, containing a sugar in the inner and outer water phases, effective for mitigating allergic diseases, having excellent stability and preservable over a long period. SOLUTION: This treating agent is composed of a liposome containing an antigen immobilized exclusively in the outer water-phase of a liposome containing an amino group-containing phospholipid as a membrane-constituting component and having particle diameter of 0.1-3μm and contains a sugar in the inner and outer water-phases. This liposome-type allergy-treating agent can suppress the production of IgE, increase the formation of IgG and mitigate the allergic symptoms. The ratio of the increment in IgG production to the increment in IgE production is preferably 5-100 times the ratio of the increment in IgG production to the increment in IgE production in the case of single use of the antigen. The allergy antigen is preferably selected from mite antigen, ragweed antigen, orchard grass antigen and cedar pollen antigen.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式